Immune response to rabies vaccination in pediatric transplant patients
Version of Record online: 6 APR 2008
© 2008 Wiley Periodicals, Inc.
Volume 12, Issue 8, pages 874–877, December 2008
How to Cite
Cramer II, C. H., Shieck, V., Thomas, S. E., Kershaw, D. B., Magee, J. C. and Lopez, M. J. (2008), Immune response to rabies vaccination in pediatric transplant patients. Pediatric Transplantation, 12: 874–877. doi: 10.1111/j.1399-3046.2008.00936.x
- Issue online: 24 OCT 2008
- Version of Record online: 6 APR 2008
- Accepted for publication 16 January 2008
Abstract: Children have become engaged in a wider variety of activities as the success of solid organ transplantation has improved. These activities can result in exposure to infectious agents for which there are no data documenting the efficacy of standard treatment in children on immunosuppressive therapy. This is a retrospective review of five OLT patients and three RT patients who were potentially exposed to rabies during camp. They completed the immunoprophylaxis treatment for rabies exposure outlined by the CDC in the 2003 Red Book. Rabies titers were followed for six to 12 months post-immunization. All five OLT patients were on tacrolimus. All three RT patients were on tacrolimus, mycophenolate mofetil, and prednisone. At the time of exposure median age was 10.0 yr (8.4–17.3). None of the subjects developed rabies. A positive rabies titer, indicative of successful immunization, was present by one month in seven subjects and all subjects by six months. Rabies vaccination in pediatric transplant patients is safe and associated with the successful production of antirabies titers.